

Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-07-05 | 150 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

Market Overview:

The global digital dose inhaler market size reached US\$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 6.7 Billion by 2028, exhibiting a growth rate (CAGR) of 14.6% during 2023-2028.

Digital dose inhalers are utilized to provide a simple, accurate, and reliable dose counter, which enables asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy. These inhalers comprise sensors that record the time of medication administration and provide a low-dose warning indicator. They also offer a large display for easy accessibility and comprehension by varied patient populations. Nowadays, digital dose inhalers are integrated with Bluetooth technology that assists in pairing with a tablet, smartphone, or computer wirelessly to enable the automatic transfer of data.

Digital Dose Inhaler Market Trends:

A considerable rise in the number of individuals diagnosed with chronic respiratory diseases (CRDs), such as bronchial asthma, lung disorders, pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD), represents one of the key factors driving the demand for digital dose inhalers worldwide. Additionally, the risk of developing CRDs is increasing around the world on account of the growing number of tobacco smokers, rising levels of air pollution, and occupational dust exposure in the agriculture, forestry, and mining settings. This, in turn, is bolstering the market growth. Apart from this, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are introducing several programs to spread awareness about CRDs and the available treatments. Moreover, dry powder inhaler (DPI) systems are gaining traction as they target the delivery of fine drug particles to the deeper airways in the lungs. As a result, several manufacturers are offering capsule-based and disposable DPI devices with improved reliability, consistency, and cost-effectiveness, which is driving the market. Furthermore, favorable reimbursement policies available to the patients via government-sponsored plans and individual insurance and employee policies are boosting the treatment rates of respiratory disorders. This, in turn, is projected to stimulate the growth

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global digital dose inhaler market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type and product.

Breakup by Type:

Branded Medication
Generics Medication

Breakup by Product:

Metered Dose Inhaler
Dry Powder Inhaler

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Questions Answered in This Report

1. What was the size of the global digital dose inhaler market in 2022?
2. What is the expected growth rate of the global digital dose inhaler market during 2023-2028?
3. What are the key factors driving the global digital dose inhaler market?
4. What has been the impact of COVID-19 on the global digital dose inhaler market?
5. What is the breakup of the global digital dose inhaler market based on the type?
6. What is the breakup of the global digital dose inhaler market based on the product?
7. What are the key regions in the global digital dose inhaler market?
8. Who are the key players/companies in the global digital dose inhaler market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders
 - 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
 - 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
 - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global Digital Dose Inhaler Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Impact of COVID-19
 - 5.4 Market Forecast
- 6 Market Breakup by Type
 - 6.1 Branded Medication
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
 - 6.2 Generics Medication
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 7 Market Breakup by Product
 - 7.1 Metered Dose Inhaler
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
 - 7.2 Dry Powder Inhaler

- 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 8 Market Breakup by Region
 - 8.1 North America
 - 8.1.1 United States
 - 8.1.1.1 Market Trends
 - 8.1.1.2 Market Forecast
 - 8.1.2 Canada
 - 8.1.2.1 Market Trends
 - 8.1.2.2 Market Forecast
 - 8.2 Asia-Pacific
 - 8.2.1 China
 - 8.2.1.1 Market Trends
 - 8.2.1.2 Market Forecast
 - 8.2.2 Japan
 - 8.2.2.1 Market Trends
 - 8.2.2.2 Market Forecast
 - 8.2.3 India
 - 8.2.3.1 Market Trends
 - 8.2.3.2 Market Forecast
 - 8.2.4 South Korea
 - 8.2.4.1 Market Trends
 - 8.2.4.2 Market Forecast
 - 8.2.5 Australia
 - 8.2.5.1 Market Trends
 - 8.2.5.2 Market Forecast
 - 8.2.6 Indonesia
 - 8.2.6.1 Market Trends
 - 8.2.6.2 Market Forecast
 - 8.2.7 Others
 - 8.2.7.1 Market Trends
 - 8.2.7.2 Market Forecast
 - 8.3 Europe
 - 8.3.1 Germany
 - 8.3.1.1 Market Trends
 - 8.3.1.2 Market Forecast
 - 8.3.2 France
 - 8.3.2.1 Market Trends
 - 8.3.2.2 Market Forecast
 - 8.3.3 United Kingdom
 - 8.3.3.1 Market Trends
 - 8.3.3.2 Market Forecast
 - 8.3.4 Italy
 - 8.3.4.1 Market Trends
 - 8.3.4.2 Market Forecast
 - 8.3.5 Spain
 - 8.3.5.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.5.2 Market Forecast
- 8.3.6 Russia
 - 8.3.6.1 Market Trends
 - 8.3.6.2 Market Forecast
- 8.3.7 Others
 - 8.3.7.1 Market Trends
 - 8.3.7.2 Market Forecast
- 8.4 Latin America
 - 8.4.1 Brazil
 - 8.4.1.1 Market Trends
 - 8.4.1.2 Market Forecast
 - 8.4.2 Mexico
 - 8.4.2.1 Market Trends
 - 8.4.2.2 Market Forecast
 - 8.4.3 Others
 - 8.4.3.1 Market Trends
 - 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
 - 8.5.1 Market Trends
 - 8.5.2 Market Breakup by Country
 - 8.5.3 Market Forecast
- 9 SWOT Analysis
 - 9.1 Overview
 - 9.2 Strengths
 - 9.3 Weaknesses
 - 9.4 Opportunities
 - 9.5 Threats
- 10 Value Chain Analysis
- 11 Porters Five Forces Analysis
 - 11.1 Overview
 - 11.2 Bargaining Power of Buyers
 - 11.3 Bargaining Power of Suppliers
 - 11.4 Degree of Competition
 - 11.5 Threat of New Entrants
 - 11.6 Threat of Substitutes
- 12 Price Analysis
- 13 Competitive Landscape
 - 13.1 Market Structure
 - 13.2 Key Players
 - 13.3 Profiles of Key Players
 - 13.3.1 3M Company
 - 13.3.1.1 Company Overview
 - 13.3.1.2 Product Portfolio
 - 13.3.1.3 Financials
 - 13.3.1.4 SWOT Analysis
 - 13.3.2 AstraZeneca plc
 - 13.3.2.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 GlaxoSmithKline plc
 - 13.3.3.1 Company Overview
 - 13.3.3.2 Product Portfolio
 - 13.3.3.3 Financials
- 13.3.4 Glenmark Pharmaceuticals Limited
 - 13.3.4.1 Company Overview
 - 13.3.4.2 Product Portfolio
 - 13.3.4.3 Financials
 - 13.3.4.4 SWOT Analysis
- 13.3.5 H&T Presspart Manufacturing Ltd.
 - 13.3.5.1 Company Overview
 - 13.3.5.2 Product Portfolio
- 13.3.6 Koninklijke Philips N.V.
 - 13.3.6.1 Company Overview
 - 13.3.6.2 Product Portfolio
 - 13.3.6.3 Financials
 - 13.3.6.4 SWOT Analysis
- 13.3.7 Lupin Limited
 - 13.3.7.1 Company Overview
 - 13.3.7.2 Product Portfolio
- 13.3.8 Novartis AG
 - 13.3.8.1 Company Overview
 - 13.3.8.2 Product Portfolio
 - 13.3.8.3 Financials
 - 13.3.8.4 SWOT Analysis
- 13.3.9 OPKO Health Inc.
 - 13.3.9.1 Company Overview
 - 13.3.9.2 Product Portfolio
 - 13.3.9.3 Financials
- 13.3.10 Propeller Health (ResMed)
 - 13.3.10.1 Company Overview
 - 13.3.10.2 Product Portfolio
- 13.3.11 Sensirion AG Switzerland
 - 13.3.11.1 Company Overview
 - 13.3.11.2 Product Portfolio
 - 13.3.11.3 Financials
- 13.3.12 Teva Pharmaceutical Industries Ltd.
 - 13.3.12.1 Company Overview
 - 13.3.12.2 Product Portfolio
 - 13.3.12.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-07-05 | 150 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com